These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 19969452

  • 1. Sulfonylureido thiazoles as fructose-1,6-bisphosphatase inhibitors for the treatment of type-2 diabetes.
    Kitas E, Mohr P, Kuhn B, Hebeisen P, Wessel HP, Haap W, Ruf A, Benz J, Joseph C, Huber W, Sanchez RA, Paehler A, Benardeau A, Gubler M, Schott B, Tozzo E.
    Bioorg Med Chem Lett; 2010 Jan 15; 20(2):594-9. PubMed ID: 19969452
    [Abstract] [Full Text] [Related]

  • 2. Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase.
    Hebeisen P, Haap W, Kuhn B, Mohr P, Wessel HP, Zutter U, Kirchner S, Ruf A, Benz J, Joseph C, Alvarez-Sánchez R, Gubler M, Schott B, Benardeau A, Tozzo E, Kitas E.
    Bioorg Med Chem Lett; 2011 Jun 01; 21(11):3237-42. PubMed ID: 21550236
    [Abstract] [Full Text] [Related]

  • 3. Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.
    Dang Q, Liu Y, Cashion DK, Kasibhatla SR, Jiang T, Taplin F, Jacintho JD, Li H, Sun Z, Fan Y, DaRe J, Tian F, Li W, Gibson T, Lemus R, van Poelje PD, Potter SC, Erion MD.
    J Med Chem; 2011 Jan 13; 54(1):153-65. PubMed ID: 21126019
    [Abstract] [Full Text] [Related]

  • 4. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.
    Dang Q, Kasibhatla SR, Reddy KR, Jiang T, Reddy MR, Potter SC, Fujitaki JM, van Poelje PD, Huang J, Lipscomb WN, Erion MD.
    J Am Chem Soc; 2007 Dec 19; 129(50):15491-502. PubMed ID: 18041834
    [Abstract] [Full Text] [Related]

  • 5. Managlinat dialanetil, a fructose-1,6-bisphosphatase inhibitor for the treatment of type 2 diabetes.
    Wang Y, Tomlinson B.
    Curr Opin Investig Drugs; 2007 Oct 19; 8(10):849-58. PubMed ID: 17907062
    [Abstract] [Full Text] [Related]

  • 6. 2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
    Johansson L, Fotsch C, Bartberger MD, Castro VM, Chen M, Emery M, Gustafsson S, Hale C, Hickman D, Homan E, Jordan SR, Komorowski R, Li A, McRae K, Moniz G, Matsumoto G, Orihuela C, Palm G, Veniant M, Wang M, Williams M, Zhang J.
    J Med Chem; 2008 May 22; 51(10):2933-43. PubMed ID: 18419108
    [Abstract] [Full Text] [Related]

  • 7. Structure-based drug design of tricyclic 8H-indeno[1,2-d][1,3]thiazoles as potent FBPase inhibitors.
    Tsukada T, Takahashi M, Takemoto T, Kanno O, Yamane T, Kawamura S, Nishi T.
    Bioorg Med Chem Lett; 2010 Feb 01; 20(3):1004-7. PubMed ID: 20045638
    [Abstract] [Full Text] [Related]

  • 8. Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.
    Thomson SA, Banker P, Bickett DM, Boucheron JA, Carter HL, Clancy DC, Cooper JP, Dickerson SH, Garrido DM, Nolte RT, Peat AJ, Sheckler LR, Sparks SM, Tavares FX, Wang L, Wang TY, Weiel JE.
    Bioorg Med Chem Lett; 2009 Feb 15; 19(4):1177-82. PubMed ID: 19138846
    [Abstract] [Full Text] [Related]

  • 9. Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
    Vu CB, Bemis JE, Disch JS, Ng PY, Nunes JJ, Milne JC, Carney DP, Lynch AV, Smith JJ, Lavu S, Lambert PD, Gagne DJ, Jirousek MR, Schenk S, Olefsky JM, Perni RB.
    J Med Chem; 2009 Mar 12; 52(5):1275-83. PubMed ID: 19199480
    [Abstract] [Full Text] [Related]

  • 10. Substituted tetrahydropyrrolo[2,1-b]oxazol-5(6H)-ones and tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones as hypoglycemic agents.
    Aicher TD, Balkan B, Bell PA, Brand LJ, Cheon SH, Deems RO, Fell JB, Fillers WS, Fraser JD, Gao J, Knorr DC, Kahle GG, Leone CL, Nadelson J, Simpson R, Smith HC.
    J Med Chem; 1998 Nov 05; 41(23):4556-66. PubMed ID: 9804695
    [Abstract] [Full Text] [Related]

  • 11. Structure-guided design of AMP mimics that inhibit fructose-1,6-bisphosphatase with high affinity and specificity.
    Erion MD, Dang Q, Reddy MR, Kasibhatla SR, Huang J, Lipscomb WN, van Poelje PD.
    J Am Chem Soc; 2007 Dec 19; 129(50):15480-90. PubMed ID: 18041833
    [Abstract] [Full Text] [Related]

  • 12. Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.
    Dang Q, Kasibhatla SR, Xiao W, Liu Y, Dare J, Taplin F, Reddy KR, Scarlato GR, Gibson T, van Poelje PD, Potter SC, Erion MD.
    J Med Chem; 2010 Jan 14; 53(1):441-51. PubMed ID: 20055427
    [Abstract] [Full Text] [Related]

  • 13. Novel euglycemic and hypolipidemic agents. 4. Pyridyl- and quinolinyl-containing thiazolidinediones.
    Lohray BB, Bhushan V, Reddy AS, Rao PB, Reddy NJ, Harikishore P, Haritha N, Vikramadityan RK, Chakrabarti R, Rajagopalan R, Katneni K.
    J Med Chem; 1999 Jul 15; 42(14):2569-81. PubMed ID: 10411477
    [Abstract] [Full Text] [Related]

  • 14. Allosteric FBPase inhibitors gain 10(5) times in potency when simultaneously binding two neighboring AMP sites.
    Hebeisen P, Kuhn B, Kohler P, Gubler M, Huber W, Kitas E, Schott B, Benz J, Joseph C, Ruf A.
    Bioorg Med Chem Lett; 2008 Aug 15; 18(16):4708-12. PubMed ID: 18650089
    [Abstract] [Full Text] [Related]

  • 15. Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
    Reddy KA, Lohray BB, Bhushan V, Bajji AC, Reddy KV, Reddy PR, Krishna TH, Rao IN, Jajoo HK, Rao NV, Chakrabarti R, Dileepkumar T, Rajagopalan R.
    J Med Chem; 1999 Jun 03; 42(11):1927-40. PubMed ID: 10354401
    [Abstract] [Full Text] [Related]

  • 16. SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors.
    Ramtohul YK, Black C, Chan CC, Crane S, Guay J, Guiral S, Huang Z, Oballa R, Xu LJ, Zhang L, Li CS.
    Bioorg Med Chem Lett; 2010 Mar 01; 20(5):1593-7. PubMed ID: 20137926
    [Abstract] [Full Text] [Related]

  • 17. Design and synthesis of novel imidazoline derivatives with potent antihyperglycemic activity in a rat model of type 2 diabetes.
    Crane L, Anastassiadou M, El Hage S, Stigliani JL, Baziard-Mouysset G, Payard M, Leger JM, Bizot-Espiard JG, Ktorza A, Caignard DH, Renard P.
    Bioorg Med Chem; 2006 Nov 15; 14(22):7419-33. PubMed ID: 16889967
    [Abstract] [Full Text] [Related]

  • 18. Structure-based design of potent retinoid X receptor alpha agonists.
    Haffner CD, Lenhard JM, Miller AB, McDougald DL, Dwornik K, Ittoop OR, Gampe RT, Xu HE, Blanchard S, Montana VG, Consler TG, Bledsoe RK, Ayscue A, Croom D.
    J Med Chem; 2004 Apr 08; 47(8):2010-29. PubMed ID: 15056000
    [Abstract] [Full Text] [Related]

  • 19. Novel euglycemic and hypolipidemic agents. 1.
    Lohray BB, Bhushan V, Rao BP, Madhavan GR, Murali N, Rao KN, Reddy AK, Rajesh BM, Reddy PG, Chakrabarti R, Vikramadithyan RK, Rajagopalan R, Mamidi RN, Jajoo HK, Subramaniam S.
    J Med Chem; 1998 May 07; 41(10):1619-30. PubMed ID: 9572887
    [Abstract] [Full Text] [Related]

  • 20. Synthesis, SAR, and X-ray structure of tricyclic compounds as potent FBPase inhibitors.
    Tsukada T, Takahashi M, Takemoto T, Kanno O, Yamane T, Kawamura S, Nishi T.
    Bioorg Med Chem Lett; 2009 Oct 15; 19(20):5909-12. PubMed ID: 19762234
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.